These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 17896915)
1. Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Garanger E; Boturyn D; Dumy P Anticancer Agents Med Chem; 2007 Sep; 7(5):552-8. PubMed ID: 17896915 [TBL] [Abstract][Full Text] [Related]
2. Ligands for mapping alphavbeta3-integrin expression in vivo. Schottelius M; Laufer B; Kessler H; Wester HJ Acc Chem Res; 2009 Jul; 42(7):969-80. PubMed ID: 19489579 [TBL] [Abstract][Full Text] [Related]
3. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975 [TBL] [Abstract][Full Text] [Related]
4. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide. Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129 [TBL] [Abstract][Full Text] [Related]
5. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides. Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773 [TBL] [Abstract][Full Text] [Related]
6. Molecular basis for the targeted binding of RGD-containing peptide to integrin αVβ3. Yu YP; Wang Q; Liu YC; Xie Y Biomaterials; 2014 Feb; 35(5):1667-75. PubMed ID: 24268666 [TBL] [Abstract][Full Text] [Related]
7. Targeting alphavbeta3 integrin: design and applications of mono- and multifunctional RGD-based peptides and semipeptides. Auzzas L; Zanardi F; Battistini L; Burreddu P; Carta P; Rassu G; Curti C; Casiraghi G Curr Med Chem; 2010; 17(13):1255-99. PubMed ID: 20166941 [TBL] [Abstract][Full Text] [Related]
8. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Danhier F; Le Breton A; Préat V Mol Pharm; 2012 Nov; 9(11):2961-73. PubMed ID: 22967287 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. Ye Y; Bloch S; Xu B; Achilefu S J Med Chem; 2006 Apr; 49(7):2268-75. PubMed ID: 16570923 [TBL] [Abstract][Full Text] [Related]
10. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Temming K; Schiffelers RM; Molema G; Kok RJ Drug Resist Updat; 2005 Dec; 8(6):381-402. PubMed ID: 16309948 [TBL] [Abstract][Full Text] [Related]
11. RGD peptide-based non-viral gene delivery vectors targeting integrin α Fu S; Xu X; Ma Y; Zhang S; Zhang S J Drug Target; 2019 Jan; 27(1):1-11. PubMed ID: 29564914 [TBL] [Abstract][Full Text] [Related]
12. Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes. Dijkgraaf I; Rijnders AY; Soede A; Dechesne AC; van Esse GW; Brouwer AJ; Corstens FH; Boerman OC; Rijkers DT; Liskamp RM Org Biomol Chem; 2007 Mar; 5(6):935-44. PubMed ID: 17340009 [TBL] [Abstract][Full Text] [Related]
13. In Vivo Characterization of 4 Lobeek D; Franssen GM; Ma MT; Wester HJ; Decristoforo C; Oyen WJG; Boerman OC; Terry SYA; Rijpkema M J Nucl Med; 2018 Aug; 59(8):1296-1301. PubMed ID: 29626124 [TBL] [Abstract][Full Text] [Related]
14. Design and biological evaluation of ⁹⁹mTc-N₂S₂-Tat(49-57)-c(RGDyK): a hybrid radiopharmaceutical for tumors expressing α(v)β(3) integrins. Ocampo-García BE; Santos-Cuevas CL; De León-Rodríguez LM; García-Becerra R; Ordaz-Rosado D; Luna-Guitiérrez MA; Jiménez-Mancilla NP; Romero-Piña ME; Ferro-Flores G Nucl Med Biol; 2013 May; 40(4):481-7. PubMed ID: 23618768 [TBL] [Abstract][Full Text] [Related]
16. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640 [TBL] [Abstract][Full Text] [Related]
17. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide. Dijkgraaf I; Kruijtzer JA; Frielink C; Corstens FH; Oyen WJ; Liskamp RM; Boerman OC Int J Cancer; 2007 Feb; 120(3):605-10. PubMed ID: 17096340 [TBL] [Abstract][Full Text] [Related]
18. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848 [TBL] [Abstract][Full Text] [Related]
19. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region. Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970 [TBL] [Abstract][Full Text] [Related]
20. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression. Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]